Total Payments
$93,379
2024 Payments
$410.20
Companies
27
Transactions
299
Medicare Patients
1,546
Medicare Billing
$348,592
Payment Breakdown by Category
Other$63,913 (68.4%)
Food & Beverage$16,422 (17.6%)
Travel$7,126 (7.6%)
Consulting$5,724 (6.1%)
Education$194.12 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,913 | 43 | 68.4% |
| Food and Beverage | $16,422 | 209 | 17.6% |
| Travel and Lodging | $7,126 | 39 | 7.6% |
| Consulting Fee | $5,724 | 2 | 6.1% |
| Education | $194.12 | 6 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $75,375 | 155 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $6,617 | 12 | $0 (2017) |
| Amgen Inc. | $1,895 | 17 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $1,384 | 16 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $971.63 | 8 | $0 (2021) |
| Lilly USA, LLC | $781.24 | 19 | $0 (2021) |
| GlaxoSmithKline, LLC. | $735.66 | 8 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $732.80 | 6 | $0 (2019) |
| Janssen Biotech, Inc. | $640.95 | 3 | $0 (2019) |
| Celgene Corporation | $501.22 | 17 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $410.20 | 4 | Novartis Pharmaceuticals Corporation ($165.14) |
| 2023 | $4,556 | 11 | ABBVIE INC. ($3,968) |
| 2022 | $17,621 | 49 | ABBVIE INC. ($17,357) |
| 2021 | $5,491 | 21 | AbbVie Inc. ($4,729) |
| 2020 | $2,648 | 10 | AbbVie Inc. ($2,045) |
| 2019 | $25,967 | 80 | AbbVie, Inc. ($23,609) |
| 2018 | $19,238 | 57 | AbbVie, Inc. ($15,862) |
| 2017 | $17,448 | 67 | AbbVie, Inc. ($7,804) |
All Payment Transactions
299 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Davol Inc. | ARISTA AH FlexiTip (Device) | Food and Beverage | In-kind items and services | $143.88 | General |
| Category: Surgery | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $94.51 | General |
| 09/11/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $101.18 | General |
| 02/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $70.63 | General |
| Category: Dermatology | ||||||
| 11/13/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $125.79 | General |
| Category: Immunology | ||||||
| 11/12/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $118.57 | General |
| Category: Dermatology | ||||||
| 11/11/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $68.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/10/2023 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $85.23 | General |
| Category: Immunology | ||||||
| 10/31/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $111.59 | General |
| Category: Dermatology | ||||||
| 05/24/2023 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/08/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $67.48 | General |
| Category: Dermatology | ||||||
| 03/20/2023 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/14/2023 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 02/13/2023 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 02/01/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $78.71 | General |
| Category: Dermatology | ||||||
| 12/18/2022 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $44.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2022 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/17/2022 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2022 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $114.59 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.48 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $114.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $99.16 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $76.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $72.12 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 318 | 2,252 | $338,409 | $81,321 |
| 2022 | 8 | 321 | 2,159 | $317,890 | $78,658 |
| 2021 | 13 | 424 | 2,899 | $405,195 | $101,457 |
| 2020 | 12 | 483 | 3,080 | $396,319 | $87,156 |
Total Patients
1,546
Total Services
10,390
Medicare Billing
$348,592
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 1,743 | $150,308 | $32,062 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 244 | $101,623 | $26,582 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 38 | $23,961 | $5,580 | 23.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 80 | $19,629 | $5,359 | 27.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 32 | 32 | $13,554 | $4,539 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $13,755 | $3,538 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 37 | $10,990 | $2,930 | 26.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 24 | 59 | $4,589 | $730.80 | 15.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 135 | 273 | $87,633 | $28,919 | 33.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 18 | 1,625 | $157,625 | $27,730 | 17.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 38 | 38 | $13,338 | $5,531 | 41.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 91 | $21,749 | $5,454 | 25.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 28 | $16,520 | $4,764 | 28.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $11,609 | $3,658 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 23 | $5,014 | $1,861 | 37.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 62 | $4,402 | $740.89 | 16.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 24 | 2,160 | $204,660 | $35,633 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 133 | 288 | $90,168 | $32,724 | 36.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 48 | 149 | $34,862 | $9,387 | 26.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $18,419 | $6,165 | 33.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 27 | 27 | $13,494 | $5,135 | 38.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 32 | 41 | $8,693 | $3,088 | 35.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 22 | $8,542 | $2,622 | 30.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 13 | $7,472 | $2,283 | 30.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 13 | $5,447 | $1,673 | 30.7% |
About Dr. Gerald Miley, MD
Dr. Gerald Miley, MD is a Rheumatology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255385803.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerald Miley, MD has received a total of $93,379 in payments from pharmaceutical and medical device companies, with $410.20 received in 2024. These payments were reported across 299 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($63,913).
As a Medicare-enrolled provider, Miley has provided services to 1,546 Medicare beneficiaries, totaling 10,390 services with total Medicare billing of $348,592. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Boston, MA
- Active Since 05/19/2006
- Last Updated 02/10/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1255385803
Products in Payments
- RINVOQ (Biological) $20,173
- Rinvoq (Biological) $13,643
- KEVZARA SARILUMAB INJECTION (Biological) $7,062
- SKYRIZI (Biological) $5,881
- RINVOQ (Drug) $1,070
- COSENTYX (Biological) $842.88
- Repatha (Biological) $604.84
- Prolia (Biological) $556.46
- STELARA (Biological) $554.00
- BEVESPI AEROSPHERE (Drug) $498.84
- COSENTYX (Drug) $446.98
- Otezla (Drug) $444.80
- ELIQUIS (Drug) $419.87
- XARELTO (Drug) $375.21
- TALTZ (Drug) $371.45
- INVOKANA (Drug) $357.59
- Humira (Biological) $309.95
- AVYCAZ (Drug) $261.17
- Cimzia (Drug) $260.77
- JARDIANCE (Drug) $244.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Boston
Lee Simon, M.d, M.D
Rheumatology — Payments: $917,853
Rheumatology $917,853
Michael Weinblatt, Md, MD
Rheumatology — Payments: $408,548
Rheumatology $408,548
Sebastian Unizony, Md, MD
Rheumatology — Payments: $172,168
Rheumatology $172,168
Jack Bukowski, Md Phd, MD PHD
Rheumatology — Payments: $153,965
Rheumatology $153,965
Michael Brenner, Md, MD
Rheumatology — Payments: $141,423
Rheumatology $141,423
Dr. Joerg Ermann, Md, MD
Rheumatology — Payments: $131,409
Rheumatology $131,409